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An association between human herpesvirus 8 (HHV8) and multiple myeloma (MM) has been reported, though most studies have not
confirmed such association. To follow-up on a previous prospective seroepidemiological study, where HHV8 tended to associate
with MM risk, we linked five large serum banks in the Nordic countries with the Nordic cancer registries and 329 prospectively
occurring cases of MM were identified, together with 1631 control subjects matched by age and gender. The HHV8 seroprevalences
among cases and controls were similar (12 and 15%, respectively) and HHV8 seropositivity did not associate with the risk of MM,
neither when considering positivity for lytic antibodies (relative risk (RR)¼0.8, 95% confidence interval (CI)¼0.5–1.1) nor for latent
antibodies (RR¼0.6, 95% CI¼0.1–2.7). Similar risks were seen when analysis was restricted to case–control sets with at least 2
years lag before diagnosis (RR¼0.8, 95% CI¼0.5–1.2 and RR¼0.9, 95% CI¼0.1–4.2). In conclusion, the data indicate that HHV8
infection is not associated with MM.
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Rettig et al (1997) reported that HHV8 DNA was present in
bone marrow dendritic cells of multiple myeloma (MM)
patients, but subsequent studies had inconsistent findings (Olsen
et al, 1998; Beksac et al, 2001; Patel et al, 2001; Hermouet et al,
2003). Several studies found that HHV8 antibodies did not
associate with MM (MacKenzie et al, 1997; Masood et al, 1997;
Parravicini et al, 1997; Bouscary et al, 1998; Perna et al,
1998; Santarelli et al, 1998; Ablashi et al, 2000), although
one study found an association (Gao et al, 1998). However, the
large amounts of myeloma proteins in MM patients’ sera
may induce systematic measurement biases in serological assays.
We previously studied MM in a prospective study nested in a
cohort of 39057 healthy Finnish subjects (Tedeschi et al, 2001a).
Seropositivity for lytic and latent HHV8 antigens was found in 16
and 0.4% of the population, and had a nonsignificant tendency
to associate with MM risk (relative risk (RR)¼2.02, 95%
confidence interval (CI)¼0.94–4.33 and RR¼10.00, 95%
CI¼0.91–110.29, respectively), but the statistical power of our
study was limited. We have therefore performed a new study with
the same study design and HHV8 analyses, but on an independent
and much larger material.
MATERIALS AND METHODS
Cohorts
The study base was constituted of five prospectively followed
cohorts covering about 1133000 individuals who had donated
serum and/or plasma samples.
The Finnish Maternity Cohort contains serum samples from
700000 pregnant women attending maternity clinics (about 98% of
all those pregnant since 1983) in Finland for serological screening
of rubella immunity, HIV and hepatitis in week 14 of pregnancy
(Kibur et al, 2000).
The Helsinki Heart Study tested whether treatment with
gemfibrozil (a fibric acid derivative) reduces the incidence of
coronary heart disease (CHD) in middle-aged, dyslipidaemic men,
the volunteers for which were selected from men aged 40–55 years,
employed by two government agencies and five industrial
companies, and living in different parts of Finland. About 19000
men were enrolled, during 1980–1982.
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC)
Study evaluated whether daily supplementation with alpha-
tocopherol or beta-carotene would reduce the incidence of lung
cancer and other cancers (ATBC Cancer Prevention Study Group,
1994).
The Janus project was started in 1973 to collect and store blood
samples from healthy persons for later scientific use. Serum
samples from population-based invitational health examinations
from the whole Norway and from the Red Cross blood donors in
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which now covers about 315000 persons, 10% of whom are blood
donors who give 20ml of extra blood every other year to the Janus
project. At the first donation a declaration of consent is signed,
allowing use of the sera for anonymous cancer research.
The Northern Sweden Health and Disease Study includes three
major subcohorts, including the subcohort from an intervention
project that invites all individuals resident in the Va ¨sterbotten
county of Northern Sweden aged 40, 50 and 60 (during 1985–1995,
also those aged 30) for a health-promoting visit and to donate a
blood sample (fractionated into plasma, erythrocytes and buffy-
coat, all stored at  801C) for later research purposes. The project
started in 1985 and currently includes about 70000 individuals.
Identification of cases and controls
A total of 329 prospectively occurring cases of MM were identified
in the Nordic joint study base, all diagnosed more than a month
after the serum sampling. Five control subjects that had not
developed MM during and with equal length of follow-up were
matched to each case for biobank, sex, age at serum sampling (72
years), time of withdrawal of serum sample (72 months) – and in
Norway also for county of residence – and were selected at random
among all eligible controls. If controls could not be found, the
matching criteria were widened in successive steps of 71 year of
age and 71 month of storage until controls were found. The
maximum age difference between a case and any matching
controls at the serum sampling was 2.1 years and the mean age
difference was 0.9 years (standard deviation 0.6 years). The date of
serum sampling differed on average by 0.9 months between a case
and its controls (standard deviation 0.8 months). The samples
were analysed in batches, each containing max 54 samples
(typically containing nine cases and their 45 matched controls),
with the sample order assigned randomly. The record of
randomisation contained an 8–9-digit number consisting of
biobank code (one digit), running number (3–4 digits), batch
number (two digits), and location within the batch (two digits).
All serum samples were sent frozen for laboratory analysis at the
Centro di Riferimento Oncologico in Aviano, Italy, where they
were analysed by immunofluorescence for the presence of HHV8
antibodies by experienced laboratory personnel. The analysing
laboratory was blinded to all and any information about the
sample. In all, 120 serum samples from the Helsinki Heart Study,
185 serum samples from the Finnish Maternity Cohort, 258 plasma
samples from the Va ¨sterbotten study, 179 serum samples from the
ATBC Study from Finland and 1218 serum samples from the Janus
project in Norway were assessed. Samples from 11 cases and 52
controls in the Helsinki Heart Study had accidentally been
subjected to an additional freeze–thawing cycle.
Laboratory methods
HHV8 antibodies were determined using mouse monoclonal
antibody enhanced immunofluorescence assay (mIFA) (Lennette
et al, 1996) using the BCBL-1 cell line, as described elsewhere
(Tedeschi et al, 2001a). Specimens were screened at a 1/10 dilution
and positive samples were titrated up to 1/640. The samples were
always analysed in batches of up to 54 samples derived from the
same biobank. Each batch was tested together with positive (from
HHV8-positive Italian KS patients) and negative (healthy HHV-8
negative donors) serum controls. All samples were also tested with
a negative control cell line (Ramos, Burkitt lymphoma cells) and
sera reacting with Ramos cells were scored as not analysable.
In all, 376 serum samples (94 MM cases and 282 controls) were
also assessed for HHV8 DNA using a sensitive real-time (TaqMan)
PCR assay (Heid et al, 1996) that amplifies a 67bp amplicon in the
HHV8 minor capsid protein gene (open reading frame 26). DNA
was extracted using the QiAmp Blood Kit (Qiagen Gmbh, Hilden,
Germany) from 50ml serum into 50ml distilled water. The number
of genome equivalents in each sample was calculated from an EBV
DNA standard (Enbom et al, 2001). The standard curve was
created using the ABI PRISM 7900 Sequence Detection System
software (2.1.1v, Applied Biosystems, Foster City, CA, USA), by
plotting the Ct values against each known concentration of the EBV
standard. Reaction conditions were as reported previously
(Tedeschi et al, 2001b). Negative control water samples (for EBV
and for HHV8), positive control HHV8 DNA extracted from
culture supernatant of the BCBL1 cells and negative control from
the serum sample of an HHV8 seronegative healthy donor were
included in triplicate on each plate. The samples were analysed in
triplicates, including one inhibition control to which 0.5ml of the
positive control was added to control for inhibitory substances in
the samples.
Statistical analysis
The laboratory results were transmitted to the Finnish Cancer
Registry, where the code was broken and the RR of developing MM
given HHV8 seropositivity was estimated by exact conditional
logistic regression with LogXact 5 software (Cytel Software
Corporation, Cambridge, MA, USA). The RRs were adjusted for
the accidental extra freeze–thawing. The association between
latent and lytic seroreactivity was measured by the Spearman rank-
order correlation coefficient.
RESULTS
Detection of IgG antibodies to HHV8
Altogether, 277 out of 1960 (14%) and 18 out of 1960 (1%) serum
samples were HHV8 positive in IFA for lytic antibodies and for the
latent antibodies, respectively, with serum titres ranging from 1:10
to X1:640. The correlation between lytic and latent seroreactivity
was 0.22 (P¼0.004) among cases and 0.19 (Po0.001) among
controls, respectively. There was no difference in HHV8 seror-
eactivity, considering males or females (Table 1). Among the
different cohorts studied, we found a significantly higher HHV8
seroprevalence (IFA lytic was 27.9% and IFA latent was 1.7%,
respectively) among the samples from the ATBC Study (a Finnish
cohort consisting only of men, all heavy smokers).
In all, 94 serum samples from MM cases and 282 from the
controls, randomly selected, were also assessed for HHV8 DNA
using a quantitative real-time PCR assay. Viral DNA was
undetectable in all these samples tested and the other samples in
the study were therefore not tested for HHV8 DNA.
The RRs of developing MM in case of HHV8 seropositivity were
0.8 (95% CI¼0.5–1.1) and 0.6 (95% CI¼1.0–2.7), respectively,
for the presence of lytic and latent HHV-8 antibodies (Table 1); no
differences were observed when the different serum banks were
evaluated separately (Table 1).
To investigate whether the presence of as yet undiagnosed MM
may have affected the results, we also analysed the data with the
samples taken less than 2 years before diagnosis of MM was
excluded, as well as by dichotimising the study into case–control
sets with shorter or longer lag between enrolment and diagnosis.
There were no noteworthy differences in results depending on lag
(Table 2).
DISCUSSION
The prospective biobank-based study design, when used in
countries with complete nationwide case ascertainment, minimises
most of the epidemiological sources of bias. For example, reverse
causality biases are not likely to occur with the long follow-up
times between blood draw and diagnosis of cancer, and selection
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definition are also unlikely.
We evaluated whether HHV8 infection was associated with an
increased risk for MM, using the same prospective biobank-based
study design and analyses as in our previous study that had found
a nonsignificant tendency of association. We found no evidence of
increased risk of MM associated with HHV8 seropositivity. As our
current study is by far the largest ever prospective study on MM,
the data suggest that HHV-8 is not associated with risk of MM.
This conclusion is in line with several serological studies largely
performed on different MM populations (Cottoni and Uccini, 1997;
Mackenzie et al, 1997; Marcelin et al, 1997; Masood et al, 1997;
Whitby et al, 1997; Olsen et al, 1998). The single study that found
HHV8 antibodies to be common among MM patients (Gao et al,
1998) used a sensitive immunoblotting method for detection of
antibodies against the recombinant minor capsid antigen and
latent nuclear antigen of HHV8. The present study did not use
immunoblotting for measuring HHV8 antibodies, because our
previous prospective study of MM did include immunoblotting
against the viral antigens ORF65, ORF73 and ORFK8.1A, but found
no association (Tedeschi et al, 2001a). The possibility that lack
of association of the serological response to HHV8 and MM
risk patients may reflect the relatively immunodeficient state
typically associated with this malignancy is not likely, as the
samples were taken up to 25 years before diagnosis of MM. The
lack of association could conceivably be explained if MM is
associated with a specific immune defect that prevents the
generation of serologic responses to HHV8 or if it is associated
with a unique strain of HHV8 that has a different immunogenic
profile compared to the HHV8 strains found in KS (Berenson et al,
2000). However, in a recent study (Zhu et al, 2002), DNA
sequences of three antigenic regions (ORF65, ORF73 and
ORFK8.1) and the transforming hypervariable K1 ORF of HHV8
Table 1 RR of developing MM among subjects seropositive for HHV-8
MM on follow-up Healthy on follow-up RR 95% CI
IFA lytic
No 290 1393 1
Yes 39 238 0.8 (0.5–1.1)
IFA latent
No 327 1615 1
Yes 2 16 0.6 (0.1–2.7)
Females
IFA lytic
No 106 544 1
Yes 18 75 1.2 (0.7–2.2)
IFA latent
No 123 611 1
Yes 1 8 0.6 (0.0–4.7)
Males
IFA lytic
No 84 849 1
Yes 21 163 0.6 (0.3–1.0)
IFA latent
No 204 1004 1
Yes 1 8 0.6 (0.0–4.7)
FMC
IFA lytic
No 29 131 1
Yes 2 23 0.4 (0.0–1.7)
IFA latent
No 31 152 1
Yes 0 2 0
a (0–27)
HHS
IFA lytic
No 16 80 1
Yes 4 20 1.0 (0.2–3.7)
IFA latent
No 20 99 1
Yes 0 1 0
b (0–190)
ATBC
IFA lytic
No 25 104 1
Yes 7 43 0.7 (0.2–1.9)
IFA latent
No 31 145 1
Yes 1 2 2.5 (0.0–4.8)
JANUS
IFA lytic
No 183 904 1
Yes 20 111 0.9 (0.5–1.5)
IFA latent
No 202 1006 1
Yes 1 9 0.6 (0.0–4.0)
Umea ˚
IFA lytic
No 37 174 1
Yes 6 41 0.7 (0.2–1.8)
IFA latent
No 43 213 1
Yes 0 2 0
a (0–27)
RR¼relative risk; MM¼multiple myeloma; CI¼confidence interval;
IFA¼immunofluorescence assay; FMC¼Finnish Maternity Cohort; HHS¼Helsinki
Heart Study; Umea ˚ ¼The Northern Sweden Health and Disease Study;
ATBC¼Alpha Tocopherol Beta Carotene prevention study; Janus¼The Janus
biobank; Method: exact conditional logistic regression, adjustment for accidental
freeze–thawing.
aMedian unbiased estimate¼2.1.
bMedian unbiased estimate¼5.0.
Table 2 RR of developing multiple myeloma by lag between sampling
and diagnosis
MM on follow-up Healthy on follow-up RR 95% CI
Cases with lag 424 months:
IFA lytic
No 267 1288 1
Yes 37 221 0.8 (0.5–1.2)
IFA latent
No 302 1498 1
Yes 2 11 0.9 (0.1–4.2)
Cases with omedian lag (121 months)
IFA lytic
No 144 668 1
Yes 20 143 0.6 (0.4–1.1)
IFA latent
No 163 798 1
Yes 1 13 0.4 (0.0–2.6)
Cases with at least median lag (121 months)
IFA lytic
No 146 725 1
Yes 19 95 1.0 (0.5–1.7)
IFA latent
No 164 817 1
Yes 1 3 1.7 (0.0–2.1)
RR¼relative risk; MM¼multiple myeloma; CI¼confidence interval;
IFA¼immunofluorescence assay. Method: exact conditional logistic regression,
adjustment for freeze–thawing.
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dendritic cells and bone marrow stromal cells, and were shown to
be present in MM patients and normal individuals at similar
frequencies.
In summary, the tendency for association between HHV-8 and
MM in our previous smaller study could not be confirmed and our
results provide evidence against an involvement of HHV8 in MM
development.
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